Journal
CELL DEATH & DISEASE
Volume 9, Issue -, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41419-017-0238-6
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81470265, 81672997]
- National Key Research and Development Program on Precision Medicine of China [2017YFC0909800]
- Building Project of Engineering Research Center of Shanghai Science and Technology Program [16DZ2281000]
Ask authors/readers for more resources
Effective control of non-small-cell lung cancer (NSCLC) remains clinically challenging, especially during advanced stages of the disease. This study developed an adoptive T-cell treatment through expression of a chimeric antigen receptor (CAR) to target human epidermal growth factor receptor (EGFR) in NSCLC. We optimized the non-viral piggyBac transposon system to engineer human T cells for the expression of EGFR-CAR, consisting of EGFR scFv, transmembrane domain, and intracellular 4-1BB-CD3 zeta signaling domains. The modified CAR T cells exhibited expansion capability and anticancer efficacy in a time- and antigen-dependent manner in vitro as well as regression of EGFR-positive human lung cancer xenografts in vivo. EGFR-CAR T therapy is a promising strategy to improve the efficacy and potency of the adoptive immunotherapy in NSCLC. Moreover, EGFR-CAR T therapy could become a clinical application for NSCLC patients in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available